N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Hodgkin's Lymphoma, Lymphoma, Follicular
Both
Non-Hodgkin's Lymphoma, Lymphoma, Follicular
Trial Information
Inclusion Criteria:
- Adult patients (according to local regulation)
- Patients receiving first-line MabThera/Rituxan maintenance treatment for follicular
non-Hodgkin's lymphoma according to the local label and who give consent to take part
within 4 weeks after commencing treatment
Exclusion Criteria:
- Contraindications according to the Summary of Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of adverse events
Outcome Time Frame:
approximately 4 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Macedonia: Ministry of Health Pharmaceuticals Bureau
Study ID:
ML27993
NCT ID:
NCT01684865
Start Date:
October 2012
Completion Date:
December 2017
Related Keywords:
- Non-Hodgkin's Lymphoma, Lymphoma, Follicular
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
Name | Location |
|---|
